| Valuation method | Value, ¥ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 7029.69 | 51 |
| Intrinsic value (DCF) | 2324.24 | -50 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 2343.56 | -50 |
Noevir Holdings Co., Ltd. (4928.T) is a Tokyo-based company specializing in cosmetics, pharmaceuticals, and health food products, operating across Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. Founded in 1964, Noevir has built a strong presence in the consumer defensive sector, particularly in skincare, with brands like Noevir, Nameraka Honpo, and NOV hypoallergenic cosmetics. The company also produces over-the-counter pharmaceuticals, functional drinks, and nutritional supplements, catering to health-conscious consumers. Noevir distributes its products through a multi-channel network, including drug stores, supermarkets, online platforms, and approximately 2,000 Noevir beauty studios. Additionally, the company engages in contract manufacturing for cosmetics and quasi-drugs, enhancing its revenue streams. With a diversified portfolio and a focus on hypoallergenic and functional products, Noevir is well-positioned in the competitive household and personal products industry. Its strong cash position (JPY 29.2 billion) and low debt (JPY 828 million) underscore financial stability, making it a resilient player in the consumer goods market.
Noevir Holdings presents a stable investment opportunity within the consumer defensive sector, supported by its diversified product portfolio and strong financials. The company's JPY 63.8 billion revenue and JPY 7.97 billion net income reflect steady profitability, with a diluted EPS of JPY 233.34. Noevir's low beta (0.056) indicates minimal volatility relative to the market, appealing to risk-averse investors. Its robust cash position (JPY 29.2 billion) and negligible debt provide financial flexibility for growth initiatives. However, the company's reliance on the Japanese market (despite international operations) and competitive pressures in the cosmetics and OTC pharmaceutical sectors pose risks. The dividend yield (JPY 225 per share) adds income appeal, but investors should monitor consumer trends and regional expansion effectiveness.
Noevir Holdings competes in the crowded household and personal products industry, differentiating itself through hypoallergenic skincare (NOV brand) and functional health products. Its direct-to-consumer approach via beauty studios strengthens brand loyalty, while contract manufacturing diversifies revenue. However, Noevir faces intense competition from global beauty giants and local players. Its pharmaceutical segment competes with established OTC brands, requiring continuous innovation. The company's financial stability (high cash reserves, low debt) provides a competitive edge, enabling R&D and market expansion. Noevir's niche in hypoallergenic cosmetics is a strength, but limited global brand recognition compared to rivals like Shiseido restricts its premium positioning. The company's multi-segment strategy mitigates risks but demands operational efficiency to maintain margins.